Stakeholders want consistency, more examples in last FDA draft guidance on patient-focused drug development
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticals